Review of Literature

The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review

Rana Ataran 1, Ayla Bahramian 1, Zahra Jamali 1, Vahid Pishahang 2, Homayoon Sadeghi Barzegani 3, Parvin Sarbakhsh 4, Javad Yazdani 5

1 Dept. of Oral Medicine, School of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Postgraduate Student, Dept. of Orthodontics, Islamic Azad University of Tehran, Tehran, Iran.
3 Injury Epidemiology and Prevention Researcher, Dept. of Statistics and Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Dept. of Statistics and Epidemiology, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Dept. of Maxillofacial Surgery, Tabriz University of Medical Sciences, Tabriz, Iran.

ABSTRACT

Temporomandibular joint disorders (TMDs) usually present with symptoms and signs such as pain, mandibular movement, dysfunction, or joint sounds. Botulinum toxin type A (BTX-A) is a biologic toxin which inhibits skeletal muscle through hindering the production of acetylcholine in the nerve endings. This toxin is used for the treatment of hyperactivity of lateral pterygoid muscle and TMD symptoms. This comprehensive review aimed to evaluate the effect of BTX-A injections in the lateral pterygoid muscle on treatment of TMDs symptoms. In this study, online databases including Scopus, Medline, Ebsco, Cochrane, EMBASE, and Google scholar were searched for the keywords “pterygoid muscle” and “Onabotulinumtoxin A”. Twenty-four articles were eligible to be enrolled in the study. In 4 interventional studies and 20 descriptive studies, BTX-A was used for the treatment of TMDs. The dosage and number of injections were different in each study; however, the injection methods were relatively similar. Regardless of the type, number of injections, and dosage, injection of BTX-A in lateral pterygoid seems effective in reducing the click sound and other TMJ-related muscle disorders such as pain, hyperactivity, and dysfunction.

Introduction

There are different signs and symptoms indicating temporomandibular joint disorder (TMD) among which are the temporomandibular joint (TMJ) pain, mandibular movement dysfunction, and joint sounds (click or crepitus). One of the most prevalent findings in TMD patients is articular disc displacement that is the most significant cause of joint click sound. [1-2]

Lateral pterygoid muscle (LP) is one of the four pairs of masticatory muscles. It acts as a fundamental element in horizontal movements of the condyle. [3] Since this muscle attaches to the joint capsule and possibly the articular disc, [4-5] the relationship between LP dysfunction and TMDs such as anterior displacement of the disc is taken into consideration. [6-7] Accordingly, if changes in normal activities of LP is the main cause of TMDs, treatment of the individual muscle becomes necessary.

Different conservative treatments namely warm compresses, behavioral therapy, oral appliances, and drugs (such as anti-inflammatories and muscle relaxant-s), as well as low-level laser therapy are used to
Botulinum toxin is the exotoxin of a gram-positive aerobic bacterium called *Clostridium botulinum* with eight different types. [11] Botulinum toxin type A (BTX-A) is a biologic variant that temporarily inhibits the skeletal muscle through hindering the production of acetylcholine and inactivation of calcium channels in the nerve endings. [12] Numerous studies have considered BTX-A injections in LP as a treatment modality. Tintner et al. [13] used toxin injections to cure the hyper-tonicity of LP muscles and its consequent bruxism. The use of this toxin in the treatment of joint sounds was reported in 2005 with no recurrence in one-year follow-up period. [14] In another study conducted in 2004, injections of botulinum toxin for patients with articular disc displacement resulted in pain relief and return of the normal movements of the mandible. The treatment was effective and stable up to 6 weeks. [15]

Regarding the fact that pain is the main manifestation and complaint of patients with TMD, it is not surprising that most related review studies have focused on the effects of botulinum toxin in reducing pain in these patients. The main goal here was a comprehensive review about the impact of BTX-A injections in the LP muscle and treatment of any symptoms of TMDs such as joint sounds, pain, anterior displacement of the articular disc, and mandibular movement disorders in association with LP dysfunction.

### Searching Strategy

The selected online databases including Scopus, Medline, Cochrane, EMBASE, and Ebsco were searched for the keywords "pterygoid muscle" and "onabotulinumtoxin A", resulting in 28, 28, 2, 124, and 24 articles, respectively. Finally Google Scholar database was searched which resulted in no new article.

Having eliminated the duplicate articles, 139 articles were obtained in total. Out of these 139, we included those written in English, which were performed, on human between 1984 and 2015 about the BTX-A in lateral pterygoid muscle. Animal studies, those not focusing on the injection in LP, and letters to editor were excluded. Considering the above-mentioned criteria, a total of 28 articles remained.

Three of these articles [8, 16-17] were “narrative review”, all the references of which were included in the present study (within the scope of the present study); thus, those three articles were not entailed in

---

### Table 1: Interventional (experimental) studies

| Title of Study | Publication date | Type of study | Control group | Number of patients | Expected result | Result | Score of study with CONSORT checklist |
|----------------|-----------------|---------------|---------------|-------------------|----------------|--------|-------------------------------------|
| Type A botulinum toxin in the treatment of chronic facial pain associated with temporomandibular dysfunction [21] | 2001 | Intervventional (experimental) | Patients before intervention | 41 | Decreasing painful hyperactivity, Para-function and hyper-mobility | Decreasing the symptoms in 80% of patients | 14 |
| Botulinum toxin for the treatment of temporomandibular joint disk displacement: Clinical experience [20] | 2005 | Interventional (experimental) | Patients before intervention | 26 Joints [41] | Decreasing pain, dysfunction, click and increasing mouth opening | Positive changing in all cases | 18 |
| Effect of injection of botulinum toxin on lateral pterygoid muscle used together with the arthroscopy in patients with anterior disk displacement of the temporomandibular joint [22] | 2009 | Interventional (experimental) | Patients before intervention | 43 | Decreasing pain, protrusion and left side dislocation | Improvement of symptoms with BTX-A injections in addition to the standard arthroscopy | 18 |
| Botulinum toxin injection for management of temporomandibular joint clicking [2] | 2013 | Interventional (experimental) | Patients before intervention | 6 Joints [11] | Posterior returning of disk, disappearing click after one week | Significant improvement in disc position | 18 |
Table 2: Details of interventional (experimental) studies

| Title of Study                                                                 | Site of injection                  | Type of injection                  | Injections | Dose   | Underlying problem                        | Side Effects                                     |
|--------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------|--------|-------------------------------------------|-------------------------------------------------|
| Type A botulinum toxin in the treatment of chronic facial pain associated with temporomandibular dysfunction | Lateral pterygoid muscle in 8 patients | With electromyography most of the times intraoral | Second injection in 17% of patients | 200 units in each side | Painful hyperactivity and hypermobility | Temporary dysphasia and speech disorders in 1 patient |
| Botulinum toxin for the treatment of temporomandibular joint disk displacement: Clinical experience | Lateral pterygoid muscle in all patients | With electromyography at 45° angle | Once | 12.5 Units | Disfigurement of TMJ | Temporary dysphasia and speech disorders in 1 patient |
| Effect of injection of botulinum toxin on lateral pterygoid muscle used together with the arthroscopy in patients with anterior disk displacement of the temporomandibular joint | Lateral pterygoid muscle in all patients | Intraoral with stimulator with 45° angle | Once | 20 units | Anterior dislocation of disk | Temporary dystonia in 2 patients |
| Botulinum toxin injection for management of temporomandibular joint clicking | Lateral pterygoid muscle in all patients | Intraoral with Electromyography | Once | 35 units | TMJ click with anterior dislocation of disk without pain and tenderness | Temporary dysphasia and influenza-like symptoms in 1 patient |

our review. Another article [18] was excluded, as it was the preliminary report of another article; [19] so we included only the complete report. [19]

The quality of clinical trials was assessed by CONSORT checklist 2010. Accordingly, if the study met any of the CONSORT items, it was scored as 1, and in case of non-compliance, it was scored as 0 for that item; thus the CONSORT score for each study ranged from a minimum of 0 to the maximum of 37 (Table 1).

Data extracted from the 24 articles included the study title, name of the author(s), date of publication, type of the study, the underlying disorders, BTX-A dosage, site of injection, frequency of administration, and treatment outcomes, as well as the possible treatment side effects.

Out of the 24 articles included, 4 were interventional (experimental) studies (Table 1). Generally, all of these studies had reported satisfactory results for the injection of botulinum in the study groups compared with the control groups. Although in some of these studies comparison of some variables between the intervention and the control group had no statistically significant difference, an overall assessment clearly revealed that injection of botulinum toxin in the LP muscle reduced pain, click sound, mandibular deviations in jaw movements, and muscle dysfunction compared with the control group. Table 2 displays more details on the four above-mentioned studies.

Twenty articles were case-report, case series, and retrospective studies as demonstrated in detail in Table 3.

Discussion

Botulinum toxin type A is a paralytic neurotoxin whose main function is to inhibit acetylcholine release at the neuromuscular junction. The U.S. FDA has approved the use of BTX-A in treating blepharospasm, strabismus, hemifacial spasm, cervical dystonia, glabellar lines, and hyperhidrosis. BTX-A is also safely employed in treating hyperfunctional facial lines, other dystonias, spasticity, and head and neck tremor. [8] However, FDA has not firmly approved BTX-A for treatment of masticatory muscles spasm yet, which might be due to the lack of adequate researches on the issue. [3]

Injection of BTX-A in maxillofacial muscles for treatment of pain, tonicity change, and improving the symptoms of TMD has been already considered as a treatment modality by researchers. [13, 16-17] Although, no study has shown the priority of more conservative treatments such as warm and cold compression, splint therapy, physiotherapy, and so on over botulinum injection for the TMD symptoms, conservative methods should be considered as the first treatment line due to the invasiveness of injection. [2, 20]

According to the trend of the current study on the use of botulinum toxin in LP muscle, most researchers
confirmed its encouraging results in decreasing the TMD symptoms and muscle dystonia. Based on the physiopathology of the click sounds of TMJ and their possible association with inappropriate tone of LP in connection with the articular disc, [4-7] undoubtedly, relaxation and normal muscle tone can reduce the

| Title of Study                                                                 | Publication date/ type of study | Patients (n) | Injection method          | Frequency of injections | Dose of injection | Results                   | Side effects           |
|--------------------------------------------------------------------------------|---------------------------------|--------------|---------------------------|------------------------|-------------------|---------------------------|------------------------|
| Treatment of recurrent temporomandibular joint dislocation using botulinum toxin A [28] | 2014 Case report                | 40           | With electromyography     | Once                   | 15 units          | No definitive side effects|                        |
| Successful treatment of a post-polio tinnitus with type A botulinum toxin [36] | 2006 Case report                | 25           | With electromyography     | Once                   | 25 units          | No side effects            |                        |
| A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia [37] | 2007 Case report                | 20           | With electromyography     | Each 3-4 months        | 25 units          | No significant side effects|                        |
| Stroke-induced trismus in a pediatric patient: Long-term resolution with botulinum toxin A [38] | 2009 Case report                | 25           | With electromyography     | Once                   | 25 units          | No side effects            |                        |
| Jaw-opening oromandibular dystonia secondary to Wilson’s Disease treated with botulinum toxin type A [21] | 2012 Case report                | 30           | With electromyography     | Once                   | 30 units          | No side effects            |                        |
| Neurogenic temporomandibular joint dislocation treated with botulinum toxin: report of 4 cases [39] | 2010 Case report                | 25           | With electromyography     | Once                   | 25 units          | No side effects            |                        |
| Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: A case report [40] | 2004 Case report                | 25           | With electromyography     | Each 3-4 months        | 25 units          | No side effects            |                        |
| Lateral pterygoid muscle dystonia, A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy [41] | 2011 Case report                | 25           | With electromyography     | Each 3-4 months        | 25 units          | No side effects            |                        |

**Table 3: Data extracted from Case report, case series, or retrospective types articles**

1. Treating severe bruxism in patients with cerebral palsy with onabotulinumtoxin A [23]
2. Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia [24]
3. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection [25]
4. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement [13]
5. Botulinum toxin injection for the treatment of oromandibular dystonia [26]
6. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin [28]
7. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint [30]
8. Levodopa-induced peak-dose lateral jaw deviation dystonia [30]
9. Management of dystonia of the lateral pterygoid muscle with botulinum toxin type A [31]
10. Oromandibular dystonia and hormonal factors: Twelve years follow-up of a case report [32]
11. Oromandibular dystonia involving the lateral pterygoid muscles: Four cases with different complexity [33]
12. Somatosensory input and oromandibular dystonia [34]
13. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A [35]
14. Successful treatment of a post-polio tinnitus with type A botulinum toxin [36]
15. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dystonia [37]
16. Stroke-induced trismus in a pediatric patient: Long-term resolution with botulinum toxin A [38]
17. Jaw-opening oromandibular dystonia secondary to Wilson’s Disease treated with botulinum toxin type A [21]
18. Neurogenic temporomandibular joint dislocation treated with botulinum toxin: report of 4 cases [39]
19. Treatment of inferior lateral pterygoid muscle dystonia with zolpidem tartrate, botulinum toxin injections, and physical self-regulation procedures: A case report [40]
20. Lateral pterygoid muscle dystonia, A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy [41]
symptoms. [2, 20] Details of botulinum toxin injection in LP muscle in qualified extracted articles are listed in Table 2.

For many years, BTX-A has been used to treat the hyperactivity of LP muscle. [13] Rao et al. conducted a review and pointed out the results of several clinical trials and case reports which had endorsed various uses of BTX-A in maxillofacial area including in dental implants surgeries, gummy smile correction, muscle hypertrophy and spasms, headaches (such as migraine), and trigeminal neuralgia, as well as the role of botulinum toxin injection in the masseter muscle for the treatment of TMD. They noted that although toxin might decrease the muscle strength and mastication force, it would be temporary and the normal function would return when the effect of toxin vanished. [16]

In an evidence-based review, Ihde et al. [17] evaluated the therapeutic effect of botulinum on relieving chronic facial pain. They noticed adverse effects such as muscle paralysis and dysphagia in a number of patients. It was described as the temporary symptom, and recovered after a short time. They also pointed out that four weeks after beginning the treatment, about 91% of patients expressed improvement in facial pain. [17]

Song et al. [8] investigated the effects of botulinum toxin on the treatment of TMD. They aimed to collect and define a specific algorithm for treatment of TMD patients. They announced that conservative treatments such as warm compresses, behavioral therapy, oral appliances, and drugs (like anti-inflammatories and muscle relaxants) were prior to BTX-A injection. [8] Hence, toxin was recommended for patients who would not respond to conservative treatments. They also deduced a recommended dose of BTX-A in treatment of TMD patients, which was 7.5-10 of the standard unit for LP muscle, prescribed in case of sub-maxillary pain, jaw deviation, or habits such as bruxism. [8]

Emara et al. [2] assessed the effects of botulinum toxin in LP muscle for the treatment of joint click in 6 patients (11 involved joints). The electromyogram (EMG) was used to define the proper insertion site of injection. They observed that toxin injection eliminated the click sound in 10 joints during the first week and in one joint after a week. During three to four following months, recurrence of click sound was reported in only one joint. [2]

Later, von Lindren [21] evaluated the effect of botulinum toxin injections on reducing the maxillofacial muscle pain associated with TMJ dysfunction. EMG was employed during injection in muscles that were difficult to access including the lateral pterygoid muscle (8 out of 41 patients). Accordingly, localized pain was recovered in 80% of patients and remained in about half of the patients for 3 months after injection. [21]

The injection method
Due to the more difficult access to LP muscle compared with other masticatory muscles, EMG was used to determine the exact place of needle entrance. According to EMG guidance to LP, the needle may insert extra-orally anterior to the condylar neck with 45° angle. In cases of intra-oral access, the injection site would be posterior to the maxillary tuberosity with 45° angle. [2, 18-19]

Frequency of injections
In three of the experimental studies [2, 20, 22] a single injection was administered; and in one study, [21] 17% of patients received a second injection. Generally in these studies, the impact of single dose normally last until the end of the follow-up period. In all investigated cases, the first dose yielded relatively favorable outcomes and repeated doses after 2-6 months were performed to strengthen the effect of previous injection. The frequency of booster dose injection varied among the reported cases (Table 3).

Dose of injection
In the experimental studies, [2, 20-22] a dose of 12.5 to 200 units per muscle was used. Different case reports mentioned various injection doses (Table 3). With respect to the desired treatment outcome and lack of comparison with other studies, the administered dose and any definitive guideline which was used were not challenged. In an overview, it seems that researchers used proper doses of injection based on the severity of involvement; for instance, the maximum dose (150 units per muscle) was used for bruxism subsequent to cerebral palsy, [23] airway collapse caused by jaw dislocation associated with muscle dystonia, [24] and recurrent dislocation of the jaw. [25]

Adverse effects of injection
The previously reported adverse effects such as belph-
The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review

Ataran R., et al.

Alopecia, brow ptosis, and diplopia at the site of injection which were seen in the treatment of headache disorders were not matters of issue in the present research. [26] In the experimental studies, [2, 20-22] the side effects of injection were often mild or transient and were reported in quite a few percent of the patients. The majority of these studies reported only temporary unwanted symptoms such as dysphagia, difficulty in articulation, muscle weakness, transient speech disorder, and flu-like symptoms. [8] In other reviewed articles, no side effect was observed except for the temporary mild dysphagia (Table 3). There were also minor complications associated with needle injections such as bruising and local tenderness. [8]

Since none of the interventional studies reported any evidence to avoid the toxin injection in the maxillofacial muscles, the temporary problems may not be a contraindication to the use of this toxin as a treatment modality for TMD.

Conclusion

Injection of BTX-A in LP muscle, considering the different methods, frequencies and injection dosages used in different studies, would decrease the clicks and other TMJ-related disorders such as pain, hyperactivity, and dysfunction. Based on the present review, the majority of studies about the injection of botulinum toxin in LP muscle reported cases or were done as quasi-experimental studies. Hence, clinical trials and single-blind or double-blind studies assessing the effect of the toxin in LP muscle seems necessary.

Conflict of Interest

The authors of this manuscript certify no financial or other competing interest regarding this article.

References

[1] Elfving L, Helkimo M, Magnusson T. Prevalence of different temporomandibular joint sounds, with emphasis on disc-displacement, in patients with temporomandibular disorders and controls. Swed Dent J. 2002; 26: 9-19.

[2] Emara AS, Faramawey MI, Hassaan MA, Hakam MM. Botulinum toxin injection for management of temporomandibular joint clicking. Int J Oral Maxillofac Surg. 2013; 42: 759-764.

[3] Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010; 39: 197-207.

[4] Bertilsson O, Ström D. A literature survey of a hundred years of anatomic and functional lateral pterygoid muscle research. J Orofac Pain. 1995; 9: 17-23.

[5] Naidoo LC. Lateral pterygoid muscle and its relationship to the meniscus of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 82: 4-9.

[6] Juniper RP. Temporomandibular joint dysfunction: a theory based upon electromyographic studies of the lateral pterygoid muscle. Br J Oral Maxillofac Surg. 1984; 22: 1-8.

[7] Liu ZJ, Wang HY, Pu WY. A comparative electromyographic study of the lateral pterygoid muscle and arthrography in patients with temporomandibular joint disturbance syndrome sounds. J Prosthet Dent. 1989; 62: 229-233.

[8] Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007; 13: 253-260.

[9] Yazdani J, Ali Ghavimi M, Porseshahidi S, Ebrahimi H. Comparison of clinical efficacy of temporalis myofascial flap and dermal graft as interpositional material in treatment of temporomandibular joint ankylosis. J Craniofac Surg. 2010; 21: 1218-1220.

[10] Talesh KT, Motamedi MH, Yazdani J, Ghavimi A, Ghoreishizadeh A. Prevention of relapse following intraoral vertical ramus osteotomymandibular setback: can coronoidotomy help? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 111: 557-560.

[11] von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003; 61: 774-778.

[12] Brin M. Botulinum toxin therapy: basic science and overview of other therapeutic applications. Management of facial lines and wrinkles. 1th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 279-302.

[13] Tintner R, Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. Scientific and therapeutic aspects of botulinum toxin. 1th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 343-350.

[14] Bakke M, Møller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint
clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 693-700.

[15] Aquirina P, Vickers R, McKellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral Maxillofac Surg. 2004; 42: 272-273.

[16] Rao LB, Sangur R, Pradeep S. Application of Botulinum toxin type A: an arsenal in dentistry. Indian J Dent Res. 2011; 22: 440-445.

[17] Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104: e1-e11.

[18] Munhoz RP, Teive HAG, Kluppel LE, Becker N, Muller PR, Werneck LC, et al. Jaw-opening oromandibular dystonia secondary to Wilson's disease. A preliminary report of 5 cases after use of botulinum toxin type A. Mov Disord. 2010; 25: S245.

[19] Teive HAG, Kluppel LE, Munhoz RP, Becker N, Muller PR, Werneck LC. Jaw-opening oromandibular dystonia secondary to Wilson's Disease treated with botulinum toxin type A. Arquivos de Neuro-Psiquiatria. 2012; 70: 407-409.

[20] Karacalar A, Yilmaz N, Bilgici A, Bağ B, Akan H. Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience. J Craniofac Surg. 2005; 16: 476-481.

[21] von Lindern JJ. Type A botulinum toxin in the treatment of chronic facial pain associated with temporomandibular dysfunction. Acta Neurol Belg. 2001; 101: 39-41.

[22] Arinci A, Güven E, Yazar M, Başaran K, Keklik B. Effect of injection of botulinum toxin on lateral pterygoid muscle used together with the arthroscopy in patients with anterior disk displacement of the temporomandibular joint. Kulak Burun Bogaz Ihtis Derg. 2009; 19: 122-129.

[23] Deshpande S, Gormley IME, Gormley ME. Treating severe bruxism in patients with cerebral palsy with onabotulinumtoxin A. Toxicicon. 2013; 68: 112-113.

[24] Yoshida K, Iizuka T. Botulinum toxin treatment for upper airway collapse resulting from temporomandibular joint dislocation due to jaw-opening dystonia. Cranio. 2006; 24: 217-222.

[25] Ziegler CM, Haag C, Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003; 7: 52-55.

[26] Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006; 26: 790-800.

[27] Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989; 98: 93-97.

[28] Daelen B, Thorwirth V, Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg. 1997; 26: 458-460.

[29] Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg. 2010; 48: 281-284.

[30] Pfeiffer RF, LeDoux MS. Levodopa-induced peak-dose lateral jaw deviation dystonia. Movement Disorders. 2014; 29 Suppl 1: S388-S389.

[31] Mendes RA, Upton LG. Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg. 2009; 47: 481-483.

[32] Michelotti A, Silva R, Paduano S, Cimino R, Farella M. Oromandibular dystonia and hormonal factors: twelve years follow-up of a case report. J Oral Rehabil. 2009; 36: 916-921.

[33] Möller E, Bakke M, Dalager T, Werdelin LM. Oromandibular dystonia involving the lateral pterygoid muscles: four cases with different complexity. Mov Disord. 2007; 22: 785-790.

[34] Möller E, Bakke M, Dalager T, Werdelin LM, Lounsdale MN, Højgaard L, et al. Somatosensory input and oromandibular dystonia. Clin Neuro Neurosurg. 2013; 115: 1141-1143.

[35] Moore AP, Wood GD. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J. 1997; 183: 415-417.

[36] Scolozzi P, Carrera E, Jaques B, Kuntzer T. Successful treatment of a postpolio tinnitus with type a botulinum toxin. Laryngoscope. 2005; 115: 1288-1290.

[37] Singer C, Papapetropoulos S. A comparison of jaw-closing and jaw-opening idiopathic oromandibular dysto-
nia. Parkinsonism Relat Disord. 2006; 12: 115-118.

[38] Spillane KS, Shelton JE, Hasty MF. Stroke-induced trismus in a pediatric patient: long-term resolution with botulinum toxin A. Am J Phys Med Rehabil. 2003; 82: 485-488.

[39] Vázquez Bouso O, Forteza González G, Mommsen J, Grau VG, Rodríguez Fernández J, Mateos Micas M. Neurogenic temporomandibular joint dislocation treated with botulinum toxin: report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109: e33-e37.

[40] Vazquez-Delgado E, Okeson JP. Treatment of inferior lateral pterygoid muscle dystonia with zolpidemtartrate, botulinum toxin injections, and physical self-regulation procedures: a case report. Cranio. 2004; 22: 325-329.

[41] Martos-Díaz P, Rodríguez-Campo FJ, Bances-del Castillo R, Altura-Guillén O, Cho-Lee GY, Mancha-de la-Plata M, et al. Lateral pterygoid muscle dystonia. A new technique for treatment with botulinum toxin guided by electromyography and arthroscopy. Med Oral Patol Oral Cir Bucal. 2011; 16: e96-e99.